Can-Fite BioPharma Ltd. (CANF)
USD 1.39
(-5.44%)
USD 1.39
(-5.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.19 Million USD | 18.83% |
| 2022 | -10.09 Million USD | 21.38% |
| 2021 | -12.84 Million USD | 9.17% |
| 2020 | -14.13 Million USD | -17.76% |
| 2019 | -12 Million USD | -121.78% |
| 2018 | -5.41 Million USD | 26.6% |
| 2017 | -7.37 Million USD | 14.57% |
| 2016 | -8.63 Million USD | -34.59% |
| 2015 | -6.41 Million USD | 10.06% |
| 2014 | -7.13 Million USD | 20.67% |
| 2013 | -8.99 Million USD | -50.03% |
| 2012 | -5.99 Million USD | -25.49% |
| 2011 | -4.77 Million USD | -26.89% |
| 2010 | -3.76 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.04 Million USD | 0.0% |
| 2024 Q1 | -2.04 Million USD | -11.61% |
| 2023 Q4 | -1.83 Million USD | 1.66% |
| 2023 Q2 | -1.78 Million USD | 34.22% |
| 2023 FY | -8.19 Million USD | 18.83% |
| 2023 Q1 | -2.71 Million USD | 12.03% |
| 2023 Q3 | -1.86 Million USD | -4.54% |
| 2022 Q4 | -3.08 Million USD | -19.82% |
| 2022 Q1 | -2.37 Million USD | 41.16% |
| 2022 Q2 | -2.07 Million USD | 12.66% |
| 2022 Q3 | -2.57 Million USD | -24.3% |
| 2022 FY | -10.09 Million USD | 21.38% |
| 2021 Q4 | -4.02 Million USD | -14.76% |
| 2021 FY | -12.84 Million USD | 9.17% |
| 2021 Q1 | -2.17 Million USD | 38.9% |
| 2021 Q2 | -3.13 Million USD | -44.31% |
| 2021 Q3 | -3.51 Million USD | -12.03% |
| 2020 Q3 | -2.47 Million USD | 35.29% |
| 2020 Q4 | -3.55 Million USD | -43.32% |
| 2020 Q1 | -4.27 Million USD | 7.18% |
| 2020 FY | -14.13 Million USD | -17.76% |
| 2020 Q2 | -3.83 Million USD | 10.41% |
| 2019 Q1 | -1.71 Million USD | 31.64% |
| 2019 FY | -12 Million USD | -121.78% |
| 2019 Q4 | -4.6 Million USD | -65.07% |
| 2019 Q2 | -2.89 Million USD | -69.14% |
| 2019 Q3 | -2.79 Million USD | 3.56% |
| 2018 Q4 | -2.5 Million USD | 61.29% |
| 2018 FY | -5.41 Million USD | 26.6% |
| 2018 Q2 | -1.96 Million USD | -24.34% |
| 2018 Q3 | -6.46 Million USD | -228.72% |
| 2018 Q1 | -1.58 Million USD | 34.03% |
| 2017 Q2 | -1.86 Million USD | 3.9% |
| 2017 Q3 | -1.16 Million USD | 37.45% |
| 2017 Q1 | -1.94 Million USD | 25.05% |
| 2017 Q4 | -2.39 Million USD | -105.36% |
| 2017 FY | -7.37 Million USD | 14.57% |
| 2016 Q2 | -2.12 Million USD | -28.87% |
| 2016 FY | -8.63 Million USD | -34.59% |
| 2016 Q3 | -2.27 Million USD | -7.04% |
| 2016 Q4 | -2.59 Million USD | -14.08% |
| 2016 Q1 | -1.64 Million USD | 30.96% |
| 2015 Q2 | -1.47 Million USD | -21.18% |
| 2015 Q4 | -2.38 Million USD | -77.5% |
| 2015 Q3 | -1.34 Million USD | 8.65% |
| 2015 FY | -6.41 Million USD | 10.06% |
| 2015 Q1 | -1.21 Million USD | 26.85% |
| 2014 Q2 | -2.16 Million USD | -11.9% |
| 2014 Q3 | -1.37 Million USD | 36.36% |
| 2014 FY | -7.13 Million USD | 20.67% |
| 2014 Q1 | -1.93 Million USD | 43.88% |
| 2014 Q4 | -1.65 Million USD | -20.56% |
| 2013 Q2 | -2.18 Million USD | -26.66% |
| 2013 Q4 | -3.44 Million USD | -122.01% |
| 2013 Q3 | -1.55 Million USD | 28.89% |
| 2013 Q1 | -1.72 Million USD | 17.7% |
| 2013 FY | -8.99 Million USD | -50.03% |
| 2012 Q2 | -1.25 Million USD | 19.98% |
| 2012 Q1 | -1.56 Million USD | -34.76% |
| 2012 Q4 | -2.09 Million USD | -74.43% |
| 2012 Q3 | -1.2 Million USD | 4.01% |
| 2012 FY | -5.99 Million USD | -25.49% |
| 2011 Q2 | -1.26 Million USD | 16.38% |
| 2011 Q4 | -1.15 Million USD | -10.47% |
| 2011 Q3 | -1.04 Million USD | 16.9% |
| 2011 FY | -4.77 Million USD | -26.89% |
| 2011 Q1 | -1.51 Million USD | -34.67% |
| 2010 Q3 | -872.67 Thousand USD | 0.0% |
| 2010 Q4 | -1.12 Million USD | -28.51% |
| 2010 FY | -3.76 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 74.323% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 13.9% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 79.958% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 84.216% |
| Azitra, Inc. | -7.61 Million USD | -7.597% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -19.421% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 71.734% |
| CEL-SCI Corporation | -31.47 Million USD | 73.964% |
| iBio, Inc. | -16.63 Million USD | 50.733% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 66.866% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 59.395% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 65.518% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 41.676% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -63.802% |
| NanoViricides, Inc. | -8.51 Million USD | 3.771% |
| Oragenics, Inc. | -20.9 Million USD | 60.799% |
| BiomX Inc. | -27.68 Million USD | 70.399% |
| BiomX Inc. | -27.68 Million USD | 70.399% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 178.346% |
| Palatin Technologies, Inc. | -22.49 Million USD | 63.571% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 80.503% |
| Theriva Biologics, Inc. | -21.43 Million USD | 61.761% |